# Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS

> **NCT03480022** · PHASE3 · COMPLETED · sponsor: **Woman's** · enrollment: 88 (actual)

## Conditions studied

- Pre Diabetes
- Polycystic Ovary Syndrome
- Obesity Android

## Interventions

- **DRUG:** Liraglutide Pen Injector [Saxenda]
- **DRUG:** Placebo Liraglutide Pen Injector

## Key facts

- **NCT ID:** NCT03480022
- **Lead sponsor:** Woman's
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-26
- **Primary completion:** 2021-02-22
- **Final completion:** 2021-05-19
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2021-06-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03480022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03480022, "Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03480022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*